Julia Whiteker, MSN, RN

home / authors / julia-whiteker-msn-rn

Articles

Julia Whiteker Describes the ONS Breast Care SIG

Julia Whiteker Describes the ONS Breast Care SIG

Julia Whiteker, MSN, RN
May 16th 2011

Julia Whiteker Describes the ONS Breast Care SIG Online Community

Read More

Julia Whiteker on the Value of Social Media to Nurses

Julia Whiteker on the Value of Social Media to Nurses

Julia Whiteker, MSN, RN
May 13th 2011

Julia Whiteker Discusses the Value of Social Media to Oncology Nurses

Read More

Julia Whiteker on Maintaining a Social Media Community

Julia Whiteker on Maintaining a Social Media Community

Julia Whiteker, MSN, RN
May 13th 2011

Julia Whiteker from the Oncology Nursing Society Breast Care SIG on Maintaining a Social Media Community

Read More

Julia Whiteker on the ONS Breast Care SIG's Future Goals

Julia Whiteker on the ONS Breast Care SIG's Future Goals

Julia Whiteker, MSN, RN
May 12th 2011

Julia Whiteker on the Oncology Nursing Society Breast Care Special Interest Groups's Future Goals

Read More

Julia Whiteker on Guidelines for Online Communities

Julia Whiteker on Guidelines for Online Communities

Julia Whiteker, MSN, RN
May 11th 2011

Julia Whiteker on Social Media Guidelines for Online Communities

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need